Delivered Is Not Value

Healthcare investment performance is measured by more than completing a project on time and within budget

A new clinic opens on schedule.

A digital platform launches within budget.

A service line meets its implementation milestones.

The project is declared a success.

But did the investment create value?

In healthcare, leaders can become so focused on approving investments, monitoring implementation and reporting milestones that they overlook the most consequential question:

Did the investment change the organization’s performance or competitive position in the way we expected?

Delivery is an event. Value creation is an outcome.

The Business Case is a Hypothesis—Not a Guarantee

Every investment begins with a set of assumptions: demand will materialize, physicians will adopt the new system, patient volumes will grow, operating costs will improve, or a new service will strengthen market position.

These assumptions form the logic behind the business case. Yet once an investment is approved, attention often shifts from testing that logic to executing the plan.

The budget becomes the benchmark. The timeline becomes the measure of discipline. The launch becomes the milestone everyone celebrates.

Meanwhile, the original assumptions may remain untested.

A new service may attract patients but divert specialists from more valuable activities.

Technology may be implemented successfully but add little to productivity because workflows never change. An expanded facility may increase revenue while generating weaker-than-expected returns after staffing, utilization and overhead are considered.

None of these investments necessarily failed at delivery. They may have failed to deliver the value promised.

The Overlooked Cost of Being Wrong

The consequences extend beyond the money already spent.

An investment that underperforms can continue consuming leadership attention, operating capacity and future capital. Worse, it can delay a better opportunity because the organization is reluctant to acknowledge that its original assumptions were wrong.

This is where sunk-cost thinking becomes strategically expensive. Leaders may continue funding an initiative because they have already invested so much in it—not because the next dirham is likely to produce an attractive return.

The more politically visible the investment, the harder it may be to question its value.

Yet stopping, redesigning or scaling back an underperforming initiative is not automatically an admission of poor leadership. When new evidence changes the outlook, adjusting the decision can demonstrate sound governance.

The real failure is not discovering that an assumption was wrong. It is failing to learn from the evidence.

Measure What Shanged—Not Just What Was Delivered

Healthcare organizations need to distinguish three forms of performance:

• Delivery performance: Was the investment completed on time and within budget?

• Operational performance: Is the asset, service or technology being used effectively?

• Strategic value: Did it produce the financial, clinical or competitive advantage that justified the investment?

These measures are related, but they are not interchangeable.

A digital platform can meet every implementation milestone while adoption remains low.

A new specialty can achieve its volume target without generating the expected contribution margin.

A new location can increase market presence without improving the organization's position against competitors.

Before approval, leaders should define what success will look like after implementation—and when it should become visible. That means assigning accountability for benefits realization, identifying measurable outcomes, documenting the assumptions behind expected returns and setting review points at which leaders can continue, adapt or stop.

Not every strategic benefit can be reduced to immediate financial return. Clinical quality, access, resilience and future capability may also justify investment. But those outcomes should be defined and assessed, not invoked retrospectively to defend disappointing results.

The Boardroom Question

The most useful investment review is not simply, “Did we deliver the project?”

It is, “What did the organization gain—and what have we learned?”

That question connects capital allocation to accountability. It also creates a feedback loop: actual results inform future business cases, investment thresholds and resource priorities. Over time, the organization becomes better at distinguishing attractive proposals from investments that genuinely create value.

For healthcare leaders, the ultimate test is therefore not whether an investment looked compelling when approved, or whether its implementation team performed well.

Does your board evaluate investments by whether they were delivered—or whether they changed the organization’s competitive position?

At Phoenix MedStrategy, we help healthcare organizations connect strategic decisions to measurable performance, so investment choices are judged by the value they create—not merely the milestones they achieve.

Sources

Kaplan, Robert S., and David P. Norton. The Balanced Scorecard: Translating Strategy into Action. Harvard Business School Press, 1996.

McGrath, Rita Gunther, and Ian C. MacMillan. “Discovery-Driven Planning.” Harvard Business Review, July–August 1995.

Kahneman, Daniel, and Amos Tversky. “Prospect Theory: An Analysis of Decision under Risk.” Econometrica, 1979.

Jensen, Michael C. “The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems.” The Journal of Finance, 1993.